CRISPR Gene Editing Plasmids: How Miaoling Biotechnology's 100,000+ In-Stock SKUs Help Accelerate Research

CRISPR-Cas9 gene editing has become an essential tool in life science research, enabling scientists to investigate gene function, disease mechanisms, and potential therapeutic targets. However, researchers often encounter three major challenges in practice: lengthy plasmid construction timelines that delay projects, high customization costs that strain research budgets, and limited availability of ready-to-use plasmids for specific species or less commonly studied genes. Together, these challenges can slow progress from basic research to translational applications.

Addressing Research Efficiency Challenges in the Era of CRISPR Gene Editing

Miaoling Biotechnology addresses these needs through an integrated service model that combines an extensive in-stock gene vector library with custom vector construction services. Its key strengths include an inventory of more than 100,000 plasmid stock-keeping units (SKUs), international distribution across markets including China, the United States, Japan, and India, and shorter turnaround times for routine custom orders. Conventional order lead times have been reduced from seven business days to five, while in-stock products ship in an average of eight hours. For local orders, the company reports a 90% same-day delivery rate within 24 hours.

CRISPR Plasmids: Technical Capabilities and Broad Research Applications

Integrated Vector Designs for Diverse Experimental Needs

Miaoling Biotechnology's CRISPR/Cas9 plasmid portfolio incorporates vector designs intended to support a range of gene editing applications. For example, the pLV3-U6-sgRNA-Cas9-EGFP-Puro vector combines sgRNA expression, Cas9, a fluorescent reporter, and a puromycin resistance marker in an all-in-one format. By consolidating these elements into a single vector, this design can simplify experimental workflows and reduce the need to construct and deliver multiple plasmids separately.

Such vectors can be useful for gene knockout studies that require subsequent cell selection, including experiments involving cell types that are difficult to transfect, such as primary cells and neurons. Actual editing efficiency and delivery performance depend on the cell type, target sequence, delivery method, and experimental conditions.

For researchers seeking widely used CRISPR tools, Miaoling also offers general-purpose vectors such as pLentiCRISPR v2. The company's portfolio further includes dCas9-KRAB, dCas9-VP64, and dCas9-VPR constructs for transcriptional repression and activation. These systems use catalytically inactive Cas9 (dCas9) fused to functional domains to modulate endogenous gene expression without introducing the DNA cleavage associated with conventional Cas9-mediated editing.

Plasmid Resources for Multiple Species and Research Areas

Miaoling Biotechnology offers CRISPR vector resources for a range of biological systems, including mammalian cells, plants, yeast, and insects. Its plasmid collection extends beyond commonly studied human and mouse genes to include resources for specific research areas involving cattle and SARS-CoV-2.

For coronavirus-related research, for example, the company offers viral gene constructs such as ORF1b plasmids that may support studies of viral biology and the development of vaccines and therapeutics, subject to the requirements of the specific research application.

This breadth of inventory helps researchers obtain relevant plasmids more quickly and reduce delays associated with sourcing specialized constructs. When a required sequence or template is unavailable as an in-stock product, custom vector construction can provide a tailored alternative. Where appropriate, the company can also make customized resources available to the broader research community at cost.

Research Applications: From Stable Cell Lines to Gene Editing and Reporter Assays

More Efficient Generation of Lentiviral Stable Cell Lines

A research group at a university in China used Miaoling Biotechnology's pLV3-CMV series vectors to generate a stable cell line overexpressing human SRCAP. The team used lentiviral packaging and transduction to introduce the construct into cells that were difficult to transfect. CopGFP fluorescence enabled rapid identification and enrichment of reporter-positive cells.

According to the reported case, the overall experimental timeline was approximately 40% shorter than that of a conventional plasmid transfection workflow.

This example illustrates the potential advantages of lentiviral vector systems for establishing stable cell models. Third-generation self-inactivating (SIN) vector designs can enhance biosafety, while regulatory elements such as the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) can improve transgene expression and, in some vector systems, viral titer. Actual performance depends on the complete vector design and production conditions.

Gene Knockout Across Multiple Cell Models

The Shanghai Institute of Materia Medica, Chinese Academy of Sciences, has reportedly collaborated with Miaoling Biotechnology for eight years, with cumulative collaboration spending exceeding RMB 1 million. During this period, the institute has used plasmids such as pX330 and multi-sgRNA vector architectures for complex gene knockout studies.

In research involving the noncoding RNA RUVBL1AS1, the pLV3-U6-RUVBL1AS1 vector was used to drive expression of the targeting sequence under the U6 promoter, supporting gene silencing. The puromycin resistance marker enabled selection of cells carrying the vector. Related findings have been cited in multiple SCI-indexed publications.

These examples illustrate how vector selection, guide or targeting sequence design, and appropriate selection strategies can be combined to support gene perturbation studies. Experimental outcomes should be validated using assays suited to the target and research objective.

Quantitative Analysis of Promoter Activity

Zhejiang University has reportedly collaborated with Miaoling Biotechnology for nearly a decade, with cumulative collaboration spending exceeding RMB 2.5 million. Plasmid systems such as pGL3-Basic and pAxl-Fluc have been used in promoter-function studies.

Luciferase reporter assays provide a quantitative approach to evaluating promoter activity and analyzing signaling pathways. Depending on the experimental design, an internal control reporter can help normalize variation in transfection efficiency and other experimental factors. A multiple cloning site (MCS) also facilitates insertion of candidate promoter sequences for functional analysis.

Together, these vector systems support a range of research applications, from gene function studies to promoter characterization and pathway analysis.

End-to-End Support: From Plasmid Preparation to Viral Packaging

High-Purity Plasmid Preparation for Demanding Applications

Manual plasmid preparation can produce inconsistent yields, insufficient purity, or excessive endotoxin levels. Miaoling Biotechnology offers ready-to-use plasmid preparations and plasmid extraction services designed to meet a range of research requirements.

The company uses automated production equipment and high-purity, low-endotoxin processing methods. Its stated quality specifications include endotoxin levels below 0.1 EU/μg and a supercoiled DNA fraction of at least 90%. These preparations are intended for applications including AAV and lentiviral vector production, as well as vaccine-related plasmid research.

Reported delivery timelines are five to seven days for milligram-scale preparations and one to two weeks for gram-scale preparations. The company also states that it provides sequence-fidelity assurance and yield guarantees.

These services can help research teams reduce the time spent on plasmid preparation and quality control, particularly in pharmaceutical R&D and gene therapy research. Final suitability should be assessed against the specific requirements of each application.

Flexible Custom Plasmid Construction

Miaoling Biotechnology's custom construction services cover a range of project types, including empty-vector modification, overexpression plasmids, RNA interference (RNAi) constructs, gene knockout vectors, and promoter reporter plasmids.

For inserts shorter than 1,000 bp, the company reports that delivery may be possible within one week, depending on sequence complexity and project requirements. A broad selection of vector backbones and shorter turnaround times can help reduce the time and resources required during the early stages of a research project.

The company's production team also brings specialized expertise in plasmid construction and viral packaging. According to the company, its production manager holds a Ph.D. from the Wuhan Institute of Virology, Chinese Academy of Sciences, and has completed postdoctoral training at Guangzhou Women and Children's Medical Center. The manager also serves as a master's thesis supervisor at Hubei University of Technology.

High-Titer Lentiviral Packaging for Hard-to-Transfect Cells

Miaoling Biotechnology offers lentiviral packaging services with reported titers of \(1 \times 10^8\) transducing units per milliliter (TU/mL) or higher, with typical turnaround times of two to four weeks.

The company states that its lentiviral preparations undergo endotoxin reduction and are designed for in vitro and in vivo gene delivery applications, subject to the requirements of the intended experiment. Its lentiviral systems have been used for delivery into challenging cell types, including neurons, primary cells, and stem cells.

The service portfolio also includes in-stock control viruses expressing CopGFP or luciferase, as well as custom viral packaging. Combined with plasmid design and construction services, these offerings support an integrated workflow from vector development to functional validation.

Industry Recognition: Research Reach and Academic Impact

Service Scale and Customer Reach

Miaoling Biotechnology reports an in-stock inventory of more than 100,000 plasmids, placing its collection among the larger domestic inventories in China. The company serves more than 6,000 organizations nationwide, including leading universities and research institutes, and exports products to countries such as Japan, the United States, India, and Russia.

In 2025, the company reports that it fulfilled nearly 120,000 plasmid units across approximately 60,000 orders and generated RMB 34 million in revenue, up from RMB 26 million in 2024—an annual increase of approximately 30%.

These figures reflect the company's stated operating scale and its focus on making research plasmids more accessible to laboratories with diverse needs.

Supporting Research and Publication

Miaoling Biotechnology reports that its products have been cited in nearly 1,000 academic publications. Applications span tumor gene-function studies, protein purification and detection, stable cell-line generation and screening, viral transduction experiments, and promoter activity analysis.

Customer feedback frequently highlights competitive pricing, accurate sequence verification, and short delivery times.

As a company contributing to the development of Hubei's biopharmaceutical sector, Miaoling Biotechnology emphasizes five priorities: local innovation, independent development of research tools, industrial collaboration, digital services, and efficient, sustainable operations.

Certifications, Facilities, and Team Expertise

The company reports that it holds high-tech enterprise status and was named a 2025 Five-Star High-Tech Enterprise in Wuhan. Its intellectual property portfolio includes two invention patents and more than 20 utility model patents.

Miaoling Biotechnology has approximately 130 employees, with master's- and doctoral-level personnel accounting for more than 50% of its workforce. Its facilities include approximately 4,000 m² of laboratory space, comprising molecular biology laboratories, quality-control areas, cold-storage facilities, and R&D laboratories. The company also maintains a P2 laboratory for cell and viral production.

These personnel and facility resources support its plasmid production, quality-control, R&D, and viral packaging operations.

Digital Research Tools: Practical Support for Experimental Design

Miaoling Biotechnology provides free research tools for GC content analysis, repetitive-sequence analysis, and literature management. These tools help researchers assess sequence characteristics, plan primer and vector designs, and obtain preliminary technical information during experimental planning.

By providing convenient access to sequence-analysis resources, the company aims to reduce avoidable design iterations and improve the research experience.

Its broader portfolio also includes RNAi plasmid systems for gene silencing through plasmid-mediated, lentivirus-mediated, and inducible approaches. These options allow researchers to select a system suited to their experimental model and gene-regulation objectives.

Conclusion: Combining Technical Innovation with Research Accessibility

Wuhan Miaoling Biotechnology Co., Ltd. combines an in-stock plasmid library containing more than 100,000 SKUs with a range of services spanning plasmid construction, viral packaging, and stable cell-line generation. This integrated approach is designed to address common research bottlenecks involving lead times, cost, and access to specialized gene-editing tools.

From all-in-one CRISPR-Cas9 vectors and species-specific plasmid resources to high-purity plasmid preparation and high-titer lentiviral packaging, the company's products and services support a wide range of molecular biology and biomedical research workflows.

Its stated performance specifications—including five-business-day turnaround for routine custom orders, endotoxin levels below 0.1 EU/μg, and a supercoiled DNA fraction of at least 90%—are complemented by an operating model built around maintaining a broad in-stock inventory and using repeat production to help control costs.

With more than 6,000 organizations served and tens of thousands of orders fulfilled annually, Miaoling Biotechnology aims to make essential molecular biology tools more accessible and help researchers move from experimental design to data generation with greater efficiency.

https://www.miaolingbio.net
Wuhan MiaoLing Biotechnology Co., Ltd.